→ A decorated GLP-1 pioneer is retiring at Novo Nordisk. Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on
A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
Oricell Therapeutics has raised more than $110 million in what it calls a pre-IPO financing. The company is developing CAR-T therapies for solid tumors, including
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.
The competitive landscape for PD-(L)1xVEGF bispecifics is finally taking shape.
For the last couple years, much of the attention has focused on Summit Therapeutics and its lead drug ivonescimab. Now, two other challengers are revving …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844